Treatment with the Interleukin-17A-Blocking Antibody Secukinumab Does Not Interfere with the Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects: Results of an Open-Label, Parallel-Group, Randomized Single-Center Study

Our objective was to evaluate the efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A (IL-17A) monoclonal antibody (MAb) secukinumab. We used an open-label, parallel-group, randomized single-center study of 50 healthy subjects. Subjects receiv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chioato, A., Noseda, E., Stevens, M., Gaitatzis, N., Kleinschmidt, A., Picaud, H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2012
Assuntos:
Vaccines
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3485879/
https://ncbi.nlm.nih.gov/pubmed/22875601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00386-12
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados